ClinicalTrials.gg
RecruitingNCT07843797SAIL MEVOUpdated Nov 4, 2026

SAIL-MEVO: Endovascular Treatment Versus Best Medical Therapy for Distal Vessel Occlusions

An interventional study of best medical therapy and Endovascular Treatment in Medium Vessel Occlusion Stroke (MeVO), Stroke Acute and Acute Ischemic Stroke, sponsored by Hospital Universitari Vall d'Hebron Research Institute. Recruiting at 1 site in Spain. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Primary conditionIschemic StrokeRegistry: StrokeReclassifiedWhy we changed it
Registry
Stroke — the first condition term the registry derived for this study.
ClinicalTrials.gg
Ischemic Stroke
Why
  1. The study's listed conditions name Ischemic Stroke, a narrower term within Stroke.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Hospital Universitari Vall d'Hebron Research Institute · Not applicable, Interventional, and Treatment

How we know

Updated Nov 4, 2026Now RecruitingFirst site in Spain+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
420
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 137 studies in Ischemic Stroke with a site in Spain — 37 open to participants now, 46 under way, 7 of them phase 3. Ischemic Stroke · Spain.

Planned enrollment
38th of 97
420 · median 240
Started
2026
with 9 others
No phase
48 of 137
15 open now
Primary completion
2029-01
later than 35 of 45 live
Registered
133rd of 137
by date
Lead sponsor
9 of 137
Hospital Universitari Vall d'Hebron Research Institute

Among the 137 studies in Ischemic Stroke with a site in Spain, this one is the 38th largest by planned enrollment of the 97 interventional ones that give a count, is one of 10 that started in 2026, is one of 48 with no phase, reaches primary completion later than 35 of the 45 other live ones, and was the 133rd registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

37 of the 137 studies in Ischemic Stroke with a site in Spain are open now. Recruiting first, the newest first:

31 more — sign in →

All 37 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 137 studies in Ischemic Stroke with a site in Spain, or all of them as a file.
02

Study summary

Patients with acute ischemic stroke caused by distal or medium vessel occlusions (MeVOs) may experience significant disability despite receiving the current standard medical treatment. Although endovascular treatment (EVT) is an established therapy for large vessel occlusions, its benefit in MeVO stroke remains uncertain.

The SAIL-MEVO trial is a prospective, multicenter, randomized controlled trial designed to evaluate whether EVT combined with best medical therapy improves functional outcomes compared with best medical therapy alone in selected patients with acute ischemic stroke due to MeVO. Eligible participants will be randomized in a 1:1 ratio to receive either best medical therapy alone or best medical therapy plus EVT using a standardized stepwise approach consisting of aspiration thrombectomy (ADAPT) followed, when necessary, by the SAIL technique (stent retriever-assisted intra-arterial lysis).

The primary objective is to determine whether EVT increases the proportion of patients achieving functional independence (modified Rankin Scale score 0-2) at 90 days after stroke. Secondary objectives include assessment of neurological recovery, infarct volume, quality of life, patient-reported outcomes, safety, and procedural outcomes.

Read the detailed description

Acute ischemic stroke due to medium and distal vessel occlusions (MeVOs) represents a substantial proportion of ischemic strokes. While endovascular treatment (EVT) is the standard of care for proximal large vessel occlusions, recent randomized trials have not demonstrated a consistent clinical benefit of EVT in MeVO populations. These neutral findings may reflect the heterogeneity of MeVO stroke, variability in patient selection, and differences in vascular anatomy and procedural complexity.

The SAIL-MEVO trial is an investigator-initiated, prospective, multicenter, randomized, open-label, blinded-endpoint (PROBE) trial designed to evaluate whether optimized EVT improves functional outcomes compared with best medical therapy (BMT) alone in carefully selected patients with acute ischemic stroke due to MeVO.

Participants aged 18 to 80 years presenting within 12 hours from symptom onset with an isolated distal vessel occlusion (non-dominant M2-M3 middle cerebral artery, A2-A3 anterior cerebral artery, or P2-P3 posterior cerebral artery), baseline NIHSS score between 9 and 17, ASPECTS ≥6, and an AI-predicted infarct core volume \<10 mL on non-contrast CT will be eligible for enrollment.

Participants will be randomized in a 1:1 ratio to:

Best medical therapy (BMT) according to current stroke guidelines, including intravenous thrombolysis when indicated; or Best medical therapy plus endovascular treatment (EVT).

The EVT strategy consists of a standardized stepwise approach. Primary aspiration thrombectomy (ADAPT) will be performed first using a small-caliber distal aspiration catheter. If aspiration is unsuccessful or vascular anatomy prevents adequate catheter access, treatment will proceed using the SAIL technique, consisting of low-profile stent retriever deployment with localized intra-arterial thrombolysis according to the study operations manual.

The primary efficacy endpoint is functional independence, defined as a modified Rankin Scale (mRS) score of 0-2 at 90 days after randomization.

Secondary efficacy endpoints include ordinal mRS shift, excellent functional outcome (mRS 0-1), early neurological improvement, infarct volume at 24-48 hours, discharge disposition, hospital length of stay, health-related quality of life (EQ-5D-5L), return to work or usual activities, and patient-reported outcome measures.

Safety endpoints include symptomatic intracranial hemorrhage, any intracranial hemorrhage, subarachnoid hemorrhage, embolization to new territory, vessel perforation or dissection, access-site complications, device- or procedure-related serious adverse events, all-cause mortality, and serious adverse events through 90 days.

Approximately 420 participants will be enrolled across up to 10 comprehensive stroke centers. Clinical outcomes will be assessed by investigators blinded to treatment allocation, and imaging endpoints will be adjudicated by an independent central imaging core laboratory. An independent Data and Safety Monitoring Board (DSMB) will oversee participant safety throughout the study.

03

Conditions studied

  • Medium Vessel Occlusion Stroke (MeVO)
  • Stroke Acute
  • Acute Ischemic Stroke
  • Cerebral Artery Occlusion

Browse trials for

Keywords

  • Distal Vessel Occlusion
  • Medium Vessel Occlusion
  • MeVO
  • Endovascular Treatment
  • Mechanical Thrombectomy
  • Aspiration Thrombectomy
  • ADAPT
  • SAIL
  • Intra-Arterial Thrombolysis
  • Randomized Controlled Trial
  • Acute Ischemic Stroke
  • Modified Rankin Scale
  • NIHSS
  • AI Imaging
  • Infarct Core
  • Neurointervention
  • Stroke
  • PROBE Trial
04

In context

Ischemic Stroke Reclassified

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

This study's planned enrollment of 420 is above the median of 120 across 1,788 interventional studies indexed under Ischemic Stroke.

Browse Ischemic Stroke studies →

Lead sponsor

Hospital Universitari Vall d'Hebron Research Institute is the lead sponsor of 276 studies on the registry; 63 are open to participants now.

Compared within Ischemic Stroke, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Stroke. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 80 years.
  • Pre-stroke modified Rankin Scale (mRS) score of 0-1.
  • Baseline NIH Stroke Scale (NIHSS) score between 9 and 17.
  • Symptom onset to randomization less than 12 hours.
  • Acute ischemic stroke due to an isolated medium/distal vessel occlusion involving a non-dominant M2-M3 middle cerebral artery, A2-A3 anterior cerebral artery, or P2-P3 posterior cerebral artery confirmed by CTA or MRA.
  • Alberta Stroke Program Early CT Score (ASPECTS) ≥6 on non-contrast CT AND AI-predicted infarct core volume \<10 mL on non-contrast CT (when available) AND AI-defined Tmax >6s volumen >30cc on CTP (when available).
  • Written obtained from the participant or a legally authorized representative in accordance with local regulations.

Exclusion criteria

Exclusion Criteria:

  • Proximal large vessel occlusion (internal carotid artery or M1 segment) or tandem cervical internal carotid artery stenosis >70%.
  • Intracranial hemorrhage at baseline imaging.
  • Pregnancy.
  • less than 3 months.
  • Severe allergy to iodinated contrast media.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
420 participants (estimated)

Study arms

  • Active comparator
    Best Medical Therapy (BMT)

    Participants receive guideline-based best medical therapy for acute ischemic stroke, including intravenous thrombolysis when indicated according to current clinical guidelines.

    Procedure: best medical therapy

  • Experimental
    Endovascular Treatment Plus Best Medical Therapy (EVT + BMT)

    Participants receive guideline-based best medical therapy plus endovascular treatment. The endovascular strategy consists of a standardized stepwise approach using aspiration thrombectomy (ADAPT) as the first-line technique, followed by the SAIL technique (low-profile stent retriever with localized intra-arterial thrombolysis) when aspiration is unsuccessful or vascular anatomy is unfavorable.

    Procedure: best medical therapy · Procedure: Endovascular Treatment

Interventions

  • Procedurebest medical therapy

    Guideline-based medical management for acute ischemic stroke, including intravenous thrombolysis when clinically indicated according to local and international stroke guidelines.

  • ProcedureEndovascular Treatment

    Endovascular treatment using a standardized stepwise protocol. Primary aspiration thrombectomy (ADAPT) is performed first using a small-caliber distal aspiration catheter. When aspiration is unsuccessful or vascular anatomy is unfavorable, treatment proceeds with the SAIL technique, consisting of deployment of a low-profile stent retriever with localized intra-arterial thrombolysis according to the study operations manual.

07

What researchers measure

Primary outcomes

  1. Functional Independence at 90 Days

    Proportion of participants achieving functional independence, defined as a modified Rankin Scale (mRS, range 0 to 6, lower better) score of 0-2, assessed 90 (±14) days after randomization.

    Time frame: Assessment at 90 (±14) days after randomization

Secondary outcomes

  1. Ordinal Modified Rankin Scale (mRS) Score

    Distribution of modified Rankin Scale (mRS, range 0 to 6, lower better) scores

    Time frame: Assessment at 90 (±14) days after randomization

  2. Excellent Functional Outcome (mRS 0-1)

    Proportion of participants achieving a modified Rankin Scale (mRS, range 0-6, lower better) score of 0-1.

    Time frame: Assessment at 90 (±14) days after randomization

  3. Early Neurological Improvement

    Proportion of patients acheiving an early neurological improvemente defined as a reduction in National Institute of Health Stroke Scale (NIHSS, range 0-42, lower better) score of ≥8 points from baseline or an absolute NIHSS ≤2 at 24 hours.

    Time frame: 24 hours after randomization

  4. Infarct Volume

    Infarct volume measured by the central imaging core laboratory.

    Time frame: 24-48 hours after randomization

  5. Discharge Disposition

    Discharge to home versus rehabilitation or other healthcare facility.

    Time frame: At hospital discharge (up to 15 days from randomization)

  6. Length of Hospital Stay

    Duration of hospitalization measured in days.

    Time frame: At hospital discharge (up to 15 days from randomization)

  7. EQ-5D-5L Score

    Health-related quality of life assessed by the EQ-5D-5L ((EuroQol 5-Dimension, 5-Level), descriptive system and EQ VAS). Two components will be reported: the descriptive system and the EQ visual analogue scale (EQ VAS). The descriptive system comprises five dimensions - mobility, self-care, usual activities, pain/discomfort, and anxiety/depression - each evaluated from 1 to 5 (no sumatory). A lower level on a dimension indicates better health. EQ VAS (vertical visual analogue scale: ranging from 0 - 100. Higher scores indicate better health)

    Time frame: Assessment at 90 (±14) days after randomization

  8. Return to Work or Usual Activities

    Proportion of participants returning to work or usual daily activities.

    Time frame: Assesement at 90 days (+-14) after randomization

08

Study locations

1 of 1 sites recruiting
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — The patients/representants have signed an informed consent that specifies that no sharing of personal data will be performed.

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Jan 2029, 26 months later.

Of 576 non-industry interventional studies with no phase under Ischemic Stroke, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 26 months is close to that.

Counting every sponsor, half of 656 studies reached it within 27 months; a quarter within 14 and three quarters within 48.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, on Nov 4, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2026
First posted
Sep 28, 2026
StartEst.
Nov 2026was Oct 2026
Primary completionEst.
Jan 2029
CompletionEst.
Jul 2029
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 4, 2026
Sites
1 site added — first site in Spain
Show site
  • Hospital Universitari Vall d'Hebron · Barcelona, Spain
Nov 4, 2026
Start date
Oct 2026→Nov 2026
Nov 4, 2026
Sponsor
Collaborators added: Fundació Ictus
Nov 4, 2026
Registered
First appeared on the registry
Sep 28, 2026
Show all 2 updates
  1. Nov 4, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in Spain
    Show site
    • Hospital Universitari Vall d'Hebron · Barcelona, Spain
    Start date Oct 2026→Nov 2026
    Sponsor Collaborators added: Fundació Ictus
    + 1 other change: verification date
  2. Sep 28, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07843797
Collaborators
University of Iowa, Fundació Ictus
Responsible party
Sponsor
First posted
Sep 28, 2026
Start date
Nov 2026 (estimated)
Primary completion
Jan 2029 (estimated)
Completion
Jul 2029 (estimated)
Last update
Nov 4, 2026

Study contacts

Marc Ribo, MD, PhD
Contact
marcriboj@hotmail.com
934 89 30 00

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion